Quantitative analysis of the impact of neovascular age-related macular degeneration (AMD) on the UK population has led a team of researchers to call for urgent, early access to the new class of drug therapies for the disease.
Industry preview: Eye care companies announce presentations ahead of ASRS meeting
Companies in the retina space announced presentations ahead of the American Society of Retina Specialists meeting, to be held 17-20 July
PHOTON Results and Their Relation to DME Patients in Your Practice
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
Preview: The American Society of Retina Specialists meets in Stockholm, Sweden
Extended daylight hours and plentiful outdoor space make Stockholm a memorable destination for meeting attendees
PULSAR Results and Their Relation to nAMD Patients in Your Practice
John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.
EMA issues positive CHMP opinion for faricimab (Vabysmo) in third indication retinal vein occlusion
Faricimab is already approved in the EU and UK for neovascular age-related macular degeneration and diabetic macular oedema
US FDA approves biosimilar aflibercept-mrbb (Ahzantive)
The drug is a biosimilar for aflibercept 2 mg (Eylea)